

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 7, 2017

Steven N. Gersten Secretary Dynavax Technologies Corporation 2929 Seventh Street, Suite 100 Berkeley, California 94710

> Re: Dynavax Technologies Corporation Preliminary Proxy Statement on Schedule 14A

Filed June 30, 2017 File No. 001-34207

Dear Mr. Gersten:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Nikki Pope, Cooley LLP